A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Nektar Therapeutics
Related studies linked through entity extraction aliases.
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Status
- RECRUITING
- Phase
- PHASE3
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
C-TIL051 in Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
- Status
- RECRUITING
- Phase
- PHASE2
A Phase I Study of LY3471851 in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Single-Dose Study of LY3471851 in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
- Status
- WITHDRAWN
- Phase
- PHASE1
Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- Status
- TERMINATED
- Phase
- PHASE2
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
- Status
- COMPLETED
- Phase
- PHASE1
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
- Status
- COMPLETED
- Phase
- PHASE1
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
- Status
- COMPLETED
- Phase
- PHASE2
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
- Status
- TERMINATED
- Phase
- PHASE3